Homepage
Author:
Corbus Pharmaceuticals Holdings, Inc.
Posted Date:
May 14, 2026
Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors
Corbus Pharmaceuticals Holdings, Inc.
May 14, 2026
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences
Corbus Pharmaceuticals Holdings, Inc.
May 13, 2026
Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update
Corbus Pharmaceuticals Holdings, Inc.
May 12, 2026
Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026
Corbus Pharmaceuticals Holdings, Inc.
May 5, 2026
Corbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701
Corbus Pharmaceuticals Holdings, Inc.
April 22, 2026
Corbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity
Corbus Pharmaceuticals Holdings, Inc.
April 14, 2026
Corbus Pharmaceuticals Announces Broad Alignment with FDA on Registration Path for CRB-701 in Second-Line HNSCC and Cervical Cancer
Corbus Pharmaceuticals Holdings, Inc.
April 7, 2026
Corbus Pharmaceuticals to Participate in the BMO 2026 Metabolic Health Summit
Corbus Pharmaceuticals Holdings, Inc.
March 18, 2026
Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update
Corbus Pharmaceuticals Holdings, Inc.
March 9, 2026
Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference
Corbus Pharmaceuticals Holdings, Inc.
February 12, 2026
